



ABN 11 124 426 339

Level 3, 2-4 Ross Place, South Melbourne, VIC 3205

P +61 (3) 9673 9690 F +61 (3) 9673 9699

www.purifloh.com E corporate@purifloh.com

31 October 2024

ASX Announcement

Quarterly Activities and Cashflow Report for the quarter ending 30 September 2024

During the quarter ending 30 September 2024, Purifloh Limited (“Purifloh”, “the Company”, “PO3”) has continued to focus on the application of its technology to the global issue of PFAS contamination through ongoing lab research with real-world water samples, aided by its testing partner Osmoflo. In stepping toward broad commercialisation, planning is underway for pilot plant test work, which may be conducted independently and/or in collaboration with potential commercial partners. The Company is also pursuing further IP protection aided by the experience and subject matter expertise of the Company’s lead personnel, Dr Alex Sava and Vigneswaran Appia.

Research and Development (R&D)

Internal testing progressed with a focus on optimising PFAS destruction across synthetic and real-world water samples. The objectives of the optimisation include speed of treatment, minimal energy consumption, high destruction percentage, minimising additive concentration and other key technical aspects, which will also be key commercialisation and scaling factors.

The Company has relocated its R&D operations to a larger space within the CoLabs network to accommodate its expanding research requirements to provide enhanced resources and infrastructure to support advanced testing and process optimisation.

During the quarter, the Company received interest from the Department of Defence (“DoD”) and PFAS-contaminated water samples received from a classified DoD site were further pre-treated to concentrate PFAS at high levels (order of magnitude 10^6 x acceptable drinking water levels). Lab-scale tests achieved complete mineralisation of critical PFAS compounds, demonstrating the efficacy and potential of Purifloh’s process for high-contamination environments.

The board considers this to be a highly significant event in the Company’s history and has determined to focus on the Company’s efforts and resources on exploiting the opportunity to apply its multi-purpose technologies to this singular global issue.

Strategic Partnerships

The initial discovery of the Company’s Free Radical Generation technology to destroy PFAS was originally discovered partly by chance in 2023 during water testing with Osmoflo. The results facilitated a deeper engagement with Osmoflo, which in turn led to the Company’s more recent work with the DoD. This has led to an invitation for Purifloh from the DoD to submit an Expression of Interest (EOI) for pilot-level activities with the DoD.

The Company is also in discussions with Salisbury Water (Adelaide) to partner in pilot trials, with a view to further expanding the scope of real-world applications for the PFAS destruction technology. Salisbury Water manages PFAS-contaminated water, and Purifloh, having obtained contaminated water samples, demonstrated that its technology fully destroyed all PFAS compounds in lab-scale tests.

Next Steps

PurifLOH will continue advancing its technology for the application of PFAS destruction toward commercialisation and broad deployment through a strategic roadmap that includes:

- Conducting pilot trials
- Strengthening IP protection
- Deepening technical and emerging commercial partnerships
- Building industry relationships

Corporate

Following its suspension in 2023 for failing to lodge Appendix 4Gs, the Company has now lodged all its outstanding disclosures, including:

- The Audited Annual Reports for the financial years ending 30 June 2023 and 30 June 2024;
- the Audit Reviewed Half Year Accounts to 31 December 2023;
- The Notice of Meetings for the 2023 and 2024 AGMs;
- Appendix 4G's for 2022, 2023 and 2024.

The Company continues to liaise with the ASX with the aim of reinstating the quotation of its listed securities as soon as possible.

Appendix 4C – Quarterly Cashflow Report

- The Company notes that it has continued to operate on funds drawn from its debt facility with Dilato. The business is operated on the basis of essential expenditure as required and has to date been able to advance its R&D activities and commercial outcomes with relatively low expenditure.
- The Company drew down an additional \$117,000 during the quarter with undrawn and available funding of approximately \$1.9 million (refer to the attached Appendix 4C).
- A trending increase in R&D expenditure should be noted (A\$78,000), which results from alignment with commercialisation plans as well as the Company reviewing and reallocating its expenditure classifications in consultation with its advisors.
- Funds spent during the quarter were mainly on R&D costs by way of staff, rent and equipment.
- No payments were made to related parties or their associates during the quarter.

Authorised for release by the Board of PurifLOH Limited

For further information contact:

Carl Le Souef, Chairman

+61 3 9673 9673

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Purifloh Limited

ABN

11 124 426 339

Quarter ended ("current quarter")

30 September 2024

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers		
1.2 Payments for		
(a) research and development	(78)	(78)
(b) product manufacturing and operating costs		
(c) advertising and marketing		
(d) leased assets		
(e) staff costs		
(f) administration and corporate costs	(41)	(41)
1.3 Dividends received (see note 3)		
1.4 Interest received		
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
1.8 Other (provide details if material)		
1.9 Net cash from / (used in) operating activities	(119)	(119)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities		
(b) businesses		
(c) property, plant and equipment		
(d) investments		
(e) intellectual property		
(f) other non-current assets		

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
2.2 Proceeds from disposal of:		
(a) entities		
(b) businesses		
(c) property, plant and equipment		
(d) investments		
(e) intellectual property		
(f) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (provide details if material)		
2.6 Net cash from / (used in) investing activities		

3. Cash flows from financing activities		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2 Proceeds from issue of convertible debt securities		
3.3 Proceeds from exercise of options		
3.4 Transaction costs related to issues of equity securities or convertible debt securities		
3.5 Proceeds from borrowings	117	117
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (provide details if material)		
3.10 Net cash from / (used in) financing activities	117	117

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of period	5	5
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(119)	(119)
4.3 Net cash from / (used in) investing activities (item 2.6 above)		

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	117	117
4.5	Effect of movement in exchange rates on cash held		
4.6	Cash and cash equivalents at end of period	3	3

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	3	5
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	3	5

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	
6.2	Aggregate amount of payments to related parties and their associates included in item 2	
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

Quarterly cash flow report for entities subject to Listing Rule 4.7B

7. Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i>		
<i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	3,000	(1,091)
7.2 Credit standby arrangements		
7.3 Other (please specify)		
7.4 Total financing facilities	3,000	(1,091)
7.5 Unused financing facilities available at quarter end		1,909
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(119)
8.2 Cash and cash equivalents at quarter end (item 4.6)	3
8.3 Unused finance facilities available at quarter end (item 7.5)	1,909
8.4 Total available funding (item 8.2 + item 8.3)	1,912
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	16.06
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer:	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer:	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer:	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:31 October 2024.....

Authorised by:the board.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.